Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$5.03
-0.6%
$5.56
$4.34
$7.50
$51.39M0.8766,898 shs27,817 shs
FOCL
FocalTherics
$5.43
$0.00
$1.21
$5.64
$203.53M-0.0452,068 shs55,925 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.99
-0.9%
$1.03
$0.90
$1.63
$201.26M1.071.24 million shs1.09 million shs
RxSight, Inc. stock logo
RXST
RxSight
$5.06
+2.2%
$5.43
$4.48
$13.22
$209.47M1.15978,940 shs782,000 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
0.00%-8.00%-5.42%+11.45%+5.64%
FOCL
FocalTherics
0.00%+4.83%+15.04%+542,999,900.00%+542,999,900.00%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
0.00%-6.54%+4.09%-21.88%-12.28%
RxSight, Inc. stock logo
RXST
RxSight
0.00%-11.76%+5.10%-29.79%-38.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$5.03
-0.6%
$5.56
$4.34
$7.50
$51.39M0.8766,898 shs27,817 shs
FOCL
FocalTherics
$5.43
$0.00
$1.21
$5.64
$203.53M-0.0452,068 shs55,925 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.99
-0.9%
$1.03
$0.90
$1.63
$201.26M1.071.24 million shs1.09 million shs
RxSight, Inc. stock logo
RXST
RxSight
$5.06
+2.2%
$5.43
$4.48
$13.22
$209.47M1.15978,940 shs782,000 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
0.00%-8.00%-5.42%+11.45%+5.64%
FOCL
FocalTherics
0.00%+4.83%+15.04%+542,999,900.00%+542,999,900.00%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
0.00%-6.54%+4.09%-21.88%-12.28%
RxSight, Inc. stock logo
RXST
RxSight
0.00%-11.76%+5.10%-29.79%-38.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
0.00
N/AN/AN/A
FOCL
FocalTherics
2.00
Hold$6.0010.50% Upside
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
2.60
Moderate Buy$4.19322.51% Upside
RxSight, Inc. stock logo
RXST
RxSight
1.92
Reduce$8.8975.67% Upside

Current Analyst Ratings Breakdown

Latest APT, LUCD, RXST, and FOCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Set Price Target$6.50
7/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Lower Price TargetUnderperform$8.00 ➝ $6.50
7/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Reiterated RatingBuy$11.00
6/11/2026
RxSight, Inc. stock logo
RXST
RxSight
DowngradeSell (D-)Sell (E+)
6/8/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Boost Price TargetBuy$9.00 ➝ $9.25
6/2/2026
FOCL
FocalTherics
Reiterated RatingBuy$10.00
5/22/2026
RxSight, Inc. stock logo
RXST
RxSight
UpgradeSell (E+)Sell (D-)
5/15/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Lower Price TargetBuy$3.00 ➝ $2.00
5/15/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy$2.50
5/7/2026
RxSight, Inc. stock logo
RXST
RxSight
DowngradeSell (D-)Sell (E+)
5/7/2026
RxSight, Inc. stock logo
RXST
RxSight
Lower Price TargetEqual Weight$11.00 ➝ $9.00
(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$59.91M0.86$0.39 per share12.80$5.29 per share0.95
FOCL
FocalTherics
$74.07M2.75N/AN/A$0.52 per share10.44
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$5.13M39.20N/AN/A($0.31) per share-3.20
RxSight, Inc. stock logo
RXST
RxSight
$127.48M1.64N/AN/A$6.70 per share0.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
$4.19M$0.3513.59N/AN/A6.99%6.70%5.76%N/A
FOCL
FocalTherics
-$29.25M-$0.81N/AN/AN/A-41.47%-137.61%-40.62%8/27/2026 (Estimated)
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$38.94M-$1.13N/AN/AN/A-36.58%-17.01%-15.12%8/5/2026 (Estimated)

Latest APT, LUCD, RXST, and FOCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
RxSight, Inc. stock logo
RXST
RxSight
-$0.21N/AN/AN/A$32.47 millionN/A
5/13/2026Q1 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million
5/7/2026Q1 2026
FOCL
FocalTherics
-$0.22-$0.24-$0.02-$0.24$19.46 million$20.48 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
N/AN/AN/AN/AN/A
FOCL
FocalTherics
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
N/A
19.00
11.21
FOCL
FocalTherics
1.79
1.34
0.99
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
1.07
1.05
RxSight, Inc. stock logo
RXST
RxSight
N/A
10.20
8.93

Institutional Ownership

CompanyInstitutional Ownership
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
22.69%
FOCL
FocalTherics
62.74%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%
RxSight, Inc. stock logo
RXST
RxSight
78.78%

Insider Ownership

CompanyInsider Ownership
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
16.20%
FOCL
FocalTherics
10.10%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
6.90%
RxSight, Inc. stock logo
RXST
RxSight
10.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Pro Tech, Ltd. stock logo
APT
Alpha Pro Tech
12010.22 million9.46 millionOptionable
FOCL
FocalTherics
23037.48 million33.70 millionN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
70203.07 million189.06 millionNo Data
RxSight, Inc. stock logo
RXST
RxSight
22041.40 million37.24 millionOptionable

Recent News About These Companies

Piper Sandler Keeps Their Hold Rating on RxSight (RXST)
Wells Fargo Sticks to Its Hold Rating for RxSight (RXST)
RxSight Announces Preliminary Q2 Results
RxSight Stock (NASDAQ:RXST) Insider Trades
RxSight (RXST) Q1 2026 Earnings Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alpha Pro Tech stock logo

Alpha Pro Tech NYSE:APT

$5.03 -0.03 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$5.06 +0.02 (+0.50%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.

FocalTherics NASDAQ:FOCL

$5.43 0.00 (0.00%)
As of 04:00 PM Eastern

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Lucid Diagnostics stock logo

Lucid Diagnostics NASDAQ:LUCD

$0.99 -0.01 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$0.99 0.00 (-0.31%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

RxSight stock logo

RxSight NASDAQ:RXST

$5.06 +0.11 (+2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$5.07 +0.01 (+0.10%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.